Dopamine-induced changes to thalamic GABA concentration in impulsive Parkinson disease patients

Abstract

Impulsivity is inherent to behavioral disorders such as substance abuse and binge eating. While the role of dopamine in impulse behavior is well established, γ-aminobutyric acid (GABA) therapies have promise for the treatment of maladaptive behaviors. In Parkinson disease (PD), dopaminergic therapies can result in the development of impulsive and compulsive behaviors, and this clinical syndrome shares similar pathophysiology to that seen in addiction, substance abuse, and binge-eating disorders. We hypothesized that impulsive PD patients have a reduced thalamic GABAergic response to dopamine therapy. To test this hypothesis, we employed GABA magnetic resonance spectroscopy, D2-like receptor PET imaging, and clinical and quantitative measures of impulsivity in PD patients (n = 33), before and after dopamine agonist administration. We find a blunted thalamic GABA response to dopamine agonists in patients with elevated impulsivity (p = 0.027). These results emphasize how dopamine treatment differentially augments thalamic GABA concentrations, which may modify behavioral impulsivity.

Glutamate, GABA and glutathione in adults with persistent post-concussive symptoms

“…Similarly, general data analysis for advanced MRS methods such as HERMES continue to evolve, including modeling the baseline and data fitting. The tissue correction methods carried out in this study include an α-correction to account for higher GABA in GM than WM as this method is widely used in studies examining GABA+ in the literature ( Ip et al, 2021 , Bernardino et al, 2022 , Heise et al, 2022 , Stoby et al, 2022 , Trujillo et al, 2022 ). Relative GM vs WM levels of other metabolites, such as GSH and Glu are not defined ( Srinivasan et al, 2010 , An et al, 2015 , Chan et al, 2019 ).…”

Sleep disorders cause Parkinson's disease or the reverse is true: Good GABA good night

“…107,108 Furthermore, blunted GABA responses to dopamine agonists in PD patients lead to behavioral and cognitive abnormalities. 109 These annotations propose that GABAergic dysfunction in PD is associated with the progression of cognitive dysfunction. Indeed, olfactory disorders are frequent in PD, and more than 90% of PD patients have this disorder.…”

2D MXene‐Based Biosensing: A Review

“…Most of the analytes like dopamine have pico or nanomolar concentrations in the diseased conditions. [434] Therefore, it is mandatory that the designed sensor must be able to detect clinical real sample levels.…”

“…Most of the analytes like dopamine have pico or nanomolar concentrations in the diseased conditions. [ 434 ] Therefore, it is mandatory that the designed sensor must be able to detect clinical real sample levels. ✓The sensor must also be able to perform in real samples as most of the literature doesn't report the real exploitation of the designed biosensor and studies are limited to the laboratory analytes in buffer solutions only. ✓The major and most discussed challenge of MXene biosensors is the poor stability of the MXene in air, humidity, or water mediums. [ 435 ] In biosensing, we can't ignore any of these factors as they are also the main constituent of the human body.…”